Posted by Michael Wonder on 03 May 2020
Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with Ruconest
30 April 2020 - European Commission decision was received six weeks earlier than expected.
Pharming today announces that the European Commission has approved an extension in the indication of Ruconest’s (conestat alfa) marketing authorisation to include the treatment of acute angioedema attacks in children with hereditary angioedema.
This marketing authorisation expands the age range of Pharming’s lead product, Ruconest, a recombinant analogue of human C1 esterase inhibitor.
